GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gene Biotherapeutics Inc (OTCPK:CRXM) » Definitions » Total Stockholders Equity

CRXM (Gene Biotherapeutics) Total Stockholders Equity : $-3.88 Mil (As of Dec. 2020)


View and export this data going back to . Start your Free Trial

What is Gene Biotherapeutics Total Stockholders Equity?

Gene Biotherapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2020 was $-3.88 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Gene Biotherapeutics's Book Value per Share for the quarter that ended in Dec. 2020 was $-0.10. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Gene Biotherapeutics's Debt-to-Equity for the quarter that ended in Dec. 2020 was -0.33.

Gene Biotherapeutics Total Stockholders Equity Historical Data

The historical data trend for Gene Biotherapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gene Biotherapeutics Total Stockholders Equity Chart

Gene Biotherapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.14 -4.80 -5.16 -4.29 -3.88

Gene Biotherapeutics Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Dec17 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.29 -4.44 -3.07 -3.43 -3.88

Gene Biotherapeutics  (OTCPK:CRXM) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Gene Biotherapeutics's Book Value per Share for the quarter that ended in Dec. 2020 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-3.875-0)/40.3301
=-0.10

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Gene Biotherapeutics's Debt-to-Equity for the quarter that ended in Dec. 2020 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1.153 + 0.108) / -3.875
=-0.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gene Biotherapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Gene Biotherapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Gene Biotherapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gene Biotherapeutics Inc (OTCPK:CRXM) » Definitions » Total Stockholders Equity
Comparable Companies
BZYR OSL:ABT RTTR TSXV:IBT USRM XCNQ:AGN TSXV:NLTA WAR:RDG MNTMD TAUG ASX:ATX XSAT:CLINE B IMUN TSXV:COT TNTY LSE:PYC NVIV TSXV:THRM TIKRF SGBI
Traded in Other Exchanges
N/A
Address
11230 Sorrento Valley Road, Suite 220, San Diego, CA, USA, 92121
Website
https://www.genebiotherapeutics.com
Gene Biotherapeutics Inc is a clinical stage biotechnology company focused on pre-clinical, clinical, and commercialization of angiogenic gene therapy biotherapeutics for strategic niche markets primarily for the treatment of cardiovascular disease. The company's lead product candidate Generx is an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease.
Executives
Andrew M Leitch director 6615 CALLE PONTE BELLA, RANCHO SANTA FE CA 92091
Murray H Hutchison director C/O CADIZ INC., 550 SOUTH HOPE STREET, 2850, LOS ANGELES CA 90071
Dennis Mulroy officer: Chief Financial Officer
Ronald I Simon other: Former Director 485 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Robert N Weingarten director, officer: PRESIDENT and CFO 5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367